|
| Tuesday, April 28, 2026 |
|
|
CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International Expansion |
| CanSino Biologics Inc. (688185.SH/06185.HK) released its first-quarter 2026 results, reflecting a positive operational momentum. more info >> |
|
|
康希諾生物一季度業績穩健增長 全生命週期佈局打開長期價值空間 |
| 康希諾生物（688185.SH/06185.HK）4月28日發佈2026年第一季度財報。報告顯示，公司一季度實現營業收入1.90億元人民幣，同比增長38.73%，彰顯了公司在核心產品放量與降本增效策略下的強勁經營韌性。 more info >> |
|
|
康希诺生物一季度业绩稳健增长 全生命周期布局打开长期价值空间 |
| 康希诺生物（688185.SH/06185.HK）4月28日发布2026年第一季度财报。报告显示，公司一季度实现营业收入1.90亿元，同比增长38.73%，彰显了公司在核心产品放量与降本增效策略下的强劲经营韧性。 more info >> |
|
| Tuesday, March 31, 2026 |
|
|
康希諾生物扭虧為盈 創新疫苗龍頭步入價值兌現期 |
| 日前，2026年兩會政府工作報告明確提出打造生物醫藥等新興支柱產業，中國創新醫藥行業正迎來政策春風。 more info >> |
|
|
康希诺生物扭亏为盈 创新疫苗龙头步入价值兑现期 |
| 日前，2026年两会政府工作报告明确提出打造生物医药等新兴支柱产业，中国创新医药行业正迎来政策春风。 more info >> |
|
|
CanSinoBIO: From Profit Turnaround to Value Realization as an Innovative Vaccine Leader |
| China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers. In this context, CanSino Biologics Inc. (688185.SH/06185.HK) has released its Annual Results For The Year 2025, marking a return to profitability and highlighting steady progress in its commercialization efforts. more info >> |
|
| Tuesday, February 24, 2026 |
|
|
CanSinoBIO's Menhycia(R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential |
| CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the 'NMPA'), pursuant to which, the supplemental application to expand the age range of applicable population of the Company's Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the 'MCV4', trade name: Menhycia (R)) from 'children aged from 3 months to 3 years old (47 months)' to 'children aged from 3 months to 6 years old (83 months)' has been approved by NMPA. more info >> |
|
|
康希諾生物曼海欣(R)擴齡正式獲批 為公司長期價值開啟更廣闊發展空間 |
| 2026年2月24日，康希諾生物（688185.SH/06185.HK）宣佈，公司自主研發的ACYW135群腦膜炎球菌多糖結合疫苗（CRM197載體）——曼海欣(R)擴大適用人群的補充申請已正式獲得國家藥品監督管理局批准。 more info >> |
|
|
康希诺生物曼海欣(R)扩龄正式获批 为公司长期价值开启更广阔发展空间 |
| 2026年2月24日，康希诺生物（688185.SH/06185.HK）宣布，公司自主研发的ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）——曼海欣(R)扩大适用人群的补充申请已正式获得国家药品监督管理局批准。 more info >> |
|
| Wednesday, August 20, 2025 |
|
|
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle |
| In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. more info >> |
|
|
|
|
